Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alendronic acid

Drug Profile

Alendronic acid

Alternative Names: Adronat; AHButBP; Alend; Alendronate; Alendronate disodium; Alendronate sodium hydrate; Alendros; Bonalon; Bonalon Jelly; Dronal; Fosalan; Fosamax; G 704650; GTH 42; GTH-42J; GTH-42V; GTH-42W; L 670452; Marvil; MK 217; Onclast; Osteosan®; Sodium alendronate trihydrate; Teiroc

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gador; Istituto Gentili
  • Developer Teijin Pharma
  • Class Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bone disorders; Osteogenesis imperfecta
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Corticosteroid-induced osteoporosis; Fracture; Male osteoporosis; Malignant hypercalcaemia; Osteitis deformans; Osteoporosis; Postmenopausal osteoporosis
  • No development reported Bone resorption

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 05 Feb 2014 MSD Korea and Hanmi Pharmaceutical agree to co-promote alendronic acid in South Korea for prevention of osteoporosis
  • 15 Aug 2012 Registered for Osteoporosis in Japan (PO, Jelly, 35mg, once-weekly)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top